Dataset
Dataset ID:
21
Study Design
| Study Design Background | The development of advanced delivery systems, such as nanoparticles, may help overcome the blood–brain barrier (BBB) and increase brain accessibility. These systems can be exploited to improve the drugs delivery to the brain parenchyma. In addition, radiolabeled nanoparticles can be monitored in the body using positron emission tomography (PET) imaging, providing real-time insights into their pharmacokinetics and biodistribution. |
|---|---|
| Study Description | In the present work, functionalized liposomes are labeled with the radionuclide fluorine-18, exploiting a “surface radiolabeling” approach for in vivo PET imaging. |
| Study Type | preclinical |
| Study Subtype | in vitro, in vivo, ex vivo |
Publication
| Paper Linked | yes |
|---|---|
| Paper Title | Automated fluorine-18 radiolabeling via an alkyne–azide cycloaddition reaction on a dual peptide-functionalized liposome surface for in vivo PET imaging |
| Paper Authors | Marco Iannone, Marcelo Kravicz, Paolo Rainone, Antonia I. Antoniou, Stefano Stucchi, Silvia Valtorta, Arianna Amenta, Elia Anna Turolla, Sara Pellegrino, Daniele Passarella, Elisa Vino, Sergio Todde, Francesca Re, Pierfausto Seneci and Rosa Maria Moresco. |
| Affiliation | "1. Tecnomed Foundation, University of Milano-Bicocca, Monza, Italy 2. School of Medicine and Surgery,♪University of Milano-Bicocca, Monza, Italy 3. Institute of Bioimaging and Biological Complex Systems (IBSBC), National Research Council (CNR), Segrate, Italy 4. Nuclear Medicine Department, San Raffaele Scientific Institute IRCCS, Milan, Italy 5. Department of Chemistry, University of Milan, Milan, Italy, 6. National Biodiversity Future Center (NBFC), Palermo, Italy 7. GBM-BI-TRACE (GlioBlastoMa-BIcocca-TRAnslational-CEnter), University of Milano-Bicocca, Monza, Italy 8. Department of Pharmaceutical Sciences, University of Milan, Milan, Italy" |
| Paper Journal | Frontiers in Pharmacology |
| Paper Year | 2025 |
| Paper Doi | doi.org/10.3389/fphar.2025.1566257 |
| Open Access | yes |
| Updated Year | 2025 |
Study Component
| Multi Modality Images | no |
|---|---|
| Imaging Modality | PET/CT |
| Radiation | yes |
| Imaging Coverage | whole body |
| Imaging Target | tumor, brain |
Dataset Information
| Institution | IBSBC-CNR |
|---|---|
| Pi | Francesca Re |
| Co Pi | Rosa Maria Moresco |
| Country Of Institution | Italy |
| Imaging Facility | Laboratory of preclinical molecular imaging |
| Euro Bio Imaging Node | Multi-Modal Molecular Imaging Italian node (MMMI) |
| Country Of Imaging Facility | Italy |
| Funding | yes |
| Funding Agency | "Fondazione Regionale per la Ricerca Biomedica, Regione Lombardia, Project: NEVERMIND—New frontiers of engineered nanovectors to improve treatment efficacy and safety in neurological disorders (Project No. CP2_16/2018 to FR)" |
| Dataset Access | limited |
| Duo Data Use Permission | DUO:0000042 |
| Duo Data Use Modifier | DUO:0000046 |
| Duo Investigation | DUO:0000040 |
| Contact Person | paolo.rainone@cnr.it |
In Vivo Experimental Parameters
| Number Of Groups | 3 |
|---|---|
| Types Of Groups | [18F]C-Lip, [18F]D-Lip, [18F]E-Lip |
| Overall Sample Size | 9 |
| Disease Model | cancer |
| Organ Or Tissue | brain |
| Sample Size For Each Group | 3 |
| Randomization | yes, tumor growth was assessed by MRI and 18F-FLT PET performed 10 days post cells inoculation, and randomly assigned to expermental groups |
| Blinding | no |
| Statistical Methods | ANOVA Bonferroni’s multiple comparison test |
| Species | Mice |
| Strain | nude fox1 |
| Immune Status | Immunodeficient |
| Sex | female |
| Age | 7-8 weeks |
| Age At Start Experiment | 8 weeks |
| Weight | 25 g |
| Source Of Animals | Envigo RMS SRL |
| Registry Number Of Animal Authorization | n. 1174/2020-PR |
Experimental Procedures
| Pharmacological Procedures Intervention And Control | no |
|---|---|
| Blood Sampling | no |
| Surgical Procedures Including Sham Surgery | yes |
| Description Of The Surgical Procedure | Female nude mice, under general anesthesia, were intracranially injected with 500.000 Gli36ΔEGFR cells |
| Reference To Protocol | doi.org/10.3389/fonc.2021.664149 |
| Analgesic Name | isoflurane |
| Anesthesia For Imaging | yes |
| Anesthesia Type | gas |
| Duration | 20 |
| Anesthesia Drugs | isoflurane |
| Anesthesia Dose | 2% |
| Monitoring Regime | respiratoy, cardiac rate |
| Euthanasia | yes |
| Method | cervical dislocation |
| Histology | no |
| Imaging | yes |
| Frequency Of Imaging | 10, 60, 120, and 180 min after radilabelled liposome injection |
| Timing Of Imaging | 2 weeks post inoculation |
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule | yes |
| Contrast Agent Chemical Drug | 18[F]-liposome-APOE |
| Contrast Agent Dose | about 4 MBq |
| Injection Volume | about 50ul |
| Route Of Administration | intravenus |
| Cell Lines | yes |
| Cell Line | Gli36ΔEGFR |
| Provenance | Molecular Neurooncology Laboratory, MGH, Boston, MA |
Image Acquisition
| Instrument Vendor | Molecubes |
|---|---|
| Instrument Type | β-cube, X-cube |
| Instrument Specifics | PET: FOV of 72x130 mm; CT: FOV of 64x40 mm |
| Image Acquisition Parameters | CT scan (exam duration: 4 min, X-Ray beam duration: 90 s, kVp: 40, current:400 A, rotation time: 60 s, and angular views: 960), PET scanner for a 20 min static acquisition |
| Correction | PET: isotope decay and random coincidences correction; CT: ring artifact correction |
| Raw Data | yes |
Image Data
| Image Type | Processed images (reconstructed PET and CT data) |
|---|---|
| Image Scale | SUV for PET, HU for CT |
| Format Compression | DICOM |
| Dimensions | 2D/3D |
| Overall Number Of Images | 36 |
| Field Of View | Max FOV for PET and CT |
| Dimension Extents | PET/CT: 192x192x384 |
| Size Description | PET/CT: 76.8 x 76.8 x 154 mm |
| Pixel Voxel Size Description | PET/CT: 400 µm isometric |
| Image Processing Methods | CT-based normalization |
| Image Reconstruction Algorithm | PET: OSEM (30 iterations); CT: ISRA (iterative). |
| Quality Control | yes |
Analyzed Data
| Data Used For Analysis | SUV |
|---|